Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973862 | 0.82 | CA1 (0.35) | ANPEPSMN1; SMN2ALDH1A1TSHRMAPK1 | |
| SCHEMBL2637986 | 0.82 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1TSHRPOLB | |
| SCHEMBL9743398 | 0.82 | SMN1; SMN2 (0.32) | ANPEPSMN1; SMN2ALDH1A1TSHRMAPK1 | |
| SCHEMBL11670845 | 0.80 | CA1 (0.38) | ANPEPSMN1; SMN2ALDH1A1TSHRMAPK1 | |
| SCHEMBL16006410 | 0.79 | CA1 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL16866506 | 0.78 | — | — | |
| SCHEMBL15268831 | 0.78 | — | — | |
| SCHEMBL7750328 | 0.77 | ALDH1A1 (0.32) | ANPEPALDH1A1TSHRPOLB | |
| SCHEMBL16858307 | 0.77 | SLC6A2 (0.31) | CTSSCTSK | |
| SCHEMBL29055524 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0938509-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2002-11-20 | — | — | EP | claimed |
| US-6143684-A | FOR STEREOSPECIFIC POLYMERIZATION OF OLEFINS SUCH AS PROPYLENE | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 2000-11-07 | — | — | US | claimed |
| EP-0938509-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Montell Technology Company bv (NL) | 1999-09-01 | — | — | EP | claimed |
| WO-1999011677-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 1999-03-11 | — | — | WO | claimed |
| WO-2020249821-A1 | NOVEL ARGINASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-12-17 | — | — | WO | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110313167-A1 | Substituted Heterocycles as Therapeutic agents for treating cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-12-22 | — | — | US | disclosed |
| CN-101061116-A | Sulfonamide compounds | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| EP-0938509-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2002-11-20 | — | — | EP | disclosed |
| US-6239236-B1 | COMPRISING TI, MG, HALOGEN AND AN ELECTRON DONOR COMPOUND SELECTED FROM CYANOESTERS | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 2001-05-29 | — | — | US | disclosed |
| US-6143684-A | FOR STEREOSPECIFIC POLYMERIZATION OF OLEFINS SUCH AS PROPYLENE | MONTELL TECHNOLOGY COMPANY B.V. (NL) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313167-A1 | Substituted Heterocycles as Therapeutic agents for treating cancer | TP53, MDM4, MDM2 | ANPEP 3616/4885MME 2673/4885TAS1R3 4688/4885 |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | TP53, MDM4, MDM2 | ANPEP 3616/4885MME 2673/4885TAS1R3 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.